Mechanism of action

The intact GH protein binds its own receptor rather than serving only as a signal for release of another hormone molecule. De Vos et al. (1992) described a crystal structure in which one GH molecule interacts with two receptor extracellular domains through distinct binding interfaces. The FDA's Omnitrope chemistry assessment identifies the 191-residue somatropin protein and its two internal disulfide bonds. These structural features help define the intact folded molecule. A short C-terminal fragment cannot be assumed to reproduce them because it shares part of the sequence. Conversely, a stated full-length sequence does not establish the purity, folding or biological performance of an individual sample.

State of evidence

The EMA's Omnitrope assessment concerns a particular somatropin-containing medicine, specified pediatric uses and adult GH-replacement indications. Its evaluation against a reference medicine cannot be transferred automatically to any recombinant preparation. Research in healthy older people addresses a different question. Blackman et al. (2002) studied 131 participants in a randomized placebo-controlled factorial trial involving GH, sex steroids and combined interventions. Body-composition changes were not accompanied by uniform functional improvements, and adverse outcomes were frequent. Findings from a combined intervention cannot be attributed entirely to GH. Authorization for evaluated medicinal indications consequently does not establish a general anti-aging benefit. The preparation, clinical population, intervention groups and functional outcomes remain necessary context for interpreting the evidence.

Questions about the research

Is HGH 191AA interchangeable with a secretagogue or a GH fragment?

No. It is the full 191-residue hormone protein, whereas secretagogues stimulate secretion and fragments contain only part of a sequence. It also needs to be distinguished from 192-residue somatrem and alternative GH forms. These identities have separate structural and experimental contexts.

Do approved somatropin indications establish a benefit for healthy aging?

No. Medicine assessments concern particular products and evaluated indications. Trials in healthy older adults investigate another population and purpose. A change in body composition does not independently demonstrate improved function or a favorable overall clinical outcome.

Does the 191-residue label prove equivalence to a named medicine?

The label alone does not demonstrate comparable manufacturing, folding, purity or formulation. The EMA's medicine and biosimilar assessment concerns named preparations supported by data. Those conclusions cannot be applied to an unassessed research sample through its stated sequence alone.

Sources

1. de Vos et al., Science 1992DOI: 10.1126/science.1549776PMID: 1549776
2. Blackman et al., JAMA 2002DOI: 10.1001/jama.288.18.2282PMID: 12425705
3. EMA, Omnitrope European public assessment report
4. FDA, Omnitrope chemistry review 2006
5. EMA, Omnitrope current product information, pharmacokinetics section 5.2

Mechanism of action

The intact GH protein binds its own receptor rather than serving only as a signal for release of another hormone molecule. De Vos et al. (1992) described a crystal structure in which one GH molecule interacts with two receptor extracellular domains through distinct binding interfaces. The FDA's Omnitrope chemistry assessment identifies the 191-residue somatropin protein and its two internal disulfide bonds. These structural features help define the intact folded molecule. A short C-terminal fragment cannot be assumed to reproduce them because it shares part of the sequence. Conversely, a stated full-length sequence does not establish the purity, folding or biological performance of an individual sample.

State of evidence

The EMA's Omnitrope assessment concerns a particular somatropin-containing medicine, specified pediatric uses and adult GH-replacement indications. Its evaluation against a reference medicine cannot be transferred automatically to any recombinant preparation. Research in healthy older people addresses a different question. Blackman et al. (2002) studied 131 participants in a randomized placebo-controlled factorial trial involving GH, sex steroids and combined interventions. Body-composition changes were not accompanied by uniform functional improvements, and adverse outcomes were frequent. Findings from a combined intervention cannot be attributed entirely to GH. Authorization for evaluated medicinal indications consequently does not establish a general anti-aging benefit. The preparation, clinical population, intervention groups and functional outcomes remain necessary context for interpreting the evidence.

Questions about the research

Is HGH 191AA interchangeable with a secretagogue or a GH fragment?

No. It is the full 191-residue hormone protein, whereas secretagogues stimulate secretion and fragments contain only part of a sequence. It also needs to be distinguished from 192-residue somatrem and alternative GH forms. These identities have separate structural and experimental contexts.

Do approved somatropin indications establish a benefit for healthy aging?

No. Medicine assessments concern particular products and evaluated indications. Trials in healthy older adults investigate another population and purpose. A change in body composition does not independently demonstrate improved function or a favorable overall clinical outcome.

Does the 191-residue label prove equivalence to a named medicine?

The label alone does not demonstrate comparable manufacturing, folding, purity or formulation. The EMA's medicine and biosimilar assessment concerns named preparations supported by data. Those conclusions cannot be applied to an unassessed research sample through its stated sequence alone.

Sources

1. de Vos et al., Science 1992DOI: 10.1126/science.1549776PMID: 1549776
2. Blackman et al., JAMA 2002DOI: 10.1001/jama.288.18.2282PMID: 12425705
3. EMA, Omnitrope European public assessment report
4. FDA, Omnitrope chemistry review 2006
5. EMA, Omnitrope current product information, pharmacokinetics section 5.2